China Tracker - Details for Tiens Biotech (TBV)


Warning: fopen(http://finance.yahoo.com/d/quotes.csv?s=TBV&f=snl1a2xf6): failed to open stream: HTTP request failed! HTTP/1.0 403 Forbidden in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 60

Warning: fclose() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 61
 WARNING: Form 15 filed with the SEC!
 Tiens Biotech
Shares Outstanding (MRQ): 71.33 mill
New Shares / Dilution (TTM): 0.00 mill0.00%
New Shares / Dilution (since Dec 31, 2008): 0.00 mill0.00% 
Cash (MRQ): 9.69 mill7.90%
Account Receivables (MRQ): 11.28 mill9.19%
Account Receivables (Q/Q): + 1.27 mill12.65% 
Long-Term Debt (MRQ): 29.97 mill24.43%
Revenue Growth (Q/Q): 17.91% 
Revenue Growth (Y/Y): 14.44% 
Net Income Growth (Q/Q): N/A (BACK TO PROFITABILITY) 
Net Income Growth (Y/Y): -15.57%
EPS Growth (Y/Y): -15.57%
Net Margin (Q/Q): 21.1% (-4.8%)25.90% 
Net Margin (Y/Y): 21.1% (28.6%)-7.50% 
EPS | P/E (2 MRQ Projection): $0.0627.62
CFPS | P/CF (2 MRQ Projection): $0.931.86
Price/Sales (2 MRQ Projection): 2.54
Price/Book (MRQ): 0.65
Auditor: Crowe Horwath
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $0.1017.20
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2003-09-09 
Uplisting to Senior Exchange: on 2005-04-25 at $6.00 (-71.34% since Uplisting)

 Business Outlook

The merger of New Tiens with TBG pursuant to Section 253 of the DGCL became effective on August 11, 2011. New Tiens is the corporation surviving the merger, and as a result of the merger is now a privately held wholly-owned subsidiary of TIH. Pursuant to the terms of the merger, each outstanding share of common stock (other than shares held by New Tiens, shared held in treasury and shares with respect to which appraisal rights have been properly exercised and not withdrawn or lost) was converted into the right to receive $1.72 per share in cash, without interest. Notices of Merger and Appraisal Rights and Letters of Transmittal will be mailed to the former holders of such shares by the paying agent for the short-form merger as promptly as practicable, but in no event later than ten calendar days following the date the merger became effective, and should be read carefully.

The company has filed a Form 15 with the Securities and Exchange Commission on August 11, 2011 to terminate the registration of its Common Stock. Trading China is terminating coverage of Tiens Biotech, effective immediately.

(Source: SC 13E3 Filing, 2011-08-11)

We remain confident that domestic sales will return to, and potentially exceed, previous levels, as distributors begin to replenish their stock of our products. In addition, we maintain this same positive sentiment regarding international sales, which we expect will benefit from the removal of export restrictions and gradual economic improvement. We are steadfast in our commitment to building greater market share in China, expanding our international customer base, and further implementing our strategic plans for long-term domestic and international growth.

(Source: PR Newswire, 2011-03-31)

We are pleased to report an increase in domestic sales which we believe will continue in the future. Our total revenue decline should be temporary since both our domestic and global affiliated companies have not witnessed significant declines in their overall revenue. We are committed to expanding our international customer base and generating long-term domestic and international growth.

(Source: PR Newswire, 2010-11-15)

    see all Business Outlook notes
TBV
Healthcare & Drugs

COVERAGE SUSPENDED OR TERMINATED
 
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH RISK
DETAILS: Safety/Risk Model for TBV
Current Price:  $1.72
F10k Day (2003-10-24): -54.14%$3.75
2009 Close: -42.67%$3.00
2010 Close: 19.44%$1.44
High (2011-06-27): -13.14%$1.98
Low (2011-06-23): 72.00%$1.00
Exchange: PRIVATE
Market Capitalization: 122.69 mill
Total Shares: 71.33 mill
Float: n/a
Avg Volume: 49.90 k
Short Interest: 17.80 k
Short Ratio: 0.51%0.4 d
Last Quarter: 2011-03-31
Revenue (MRQ): 13.05 mill
Net Income (MRQ): 2.75 mill
Op. Cash Flow (MRQ): 6.21 mill
all financial data provided without warranty